21593114

Source:http://linkedlifedata.com/resource/pubmed/id/21593114

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0005938, umls-concept:C0043210, umls-concept:C0205251, umls-concept:C0206015, umls-concept:C0231491, umls-concept:C0232970, umls-concept:C0243127, umls-concept:C0249742, umls-concept:C0262950, umls-concept:C0443331, umls-concept:C1280500, umls-concept:C2825588
pubmed:issue	8
pubmed:dateCreated	2011-8-5
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00471237
pubmed:abstractText	Ronacaleret, a calcium-sensing receptor antagonist that stimulates PTH release from the parathyroid glands, was evaluated as an oral osteoanabolic agent for the treatment of osteoporosis.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0375362
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Alendronate, http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers, http://linkedlifedata.com/resource/pubmed/chemical/Bone Density Conservation Agents, http://linkedlifedata.com/resource/pubmed/chemical/Calcium, http://linkedlifedata.com/resource/pubmed/chemical/Indans, http://linkedlifedata.com/resource/pubmed/chemical/Parathyroid Hormone, http://linkedlifedata.com/resource/pubmed/chemical/Phenylpropionates, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Calcium-Sensing, http://linkedlifedata.com/resource/pubmed/chemical/Teriparatide, http://linkedlifedata.com/resource/pubmed/chemical/ronacaleret
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	1945-7197
pubmed:author	pubmed-author:BilezikianJohn PJP, pubmed-author:BoneHenry GHG3rd, pubmed-author:CicconettiGregoryG, pubmed-author:DabrowskiChristine ECE, pubmed-author:FitzpatrickLorraine ALA, pubmed-author:GordonDavid NDN, pubmed-author:PapapoulosSocratesS
pubmed:issnType	Electronic
pubmed:volume	96
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	2441-9
pubmed:meshHeading	pubmed-meshheading:21593114-Administration, Oral, pubmed-meshheading:21593114-Aged, pubmed-meshheading:21593114-Alendronate, pubmed-meshheading:21593114-Biological Markers, pubmed-meshheading:21593114-Bone Density, pubmed-meshheading:21593114-Bone Density Conservation Agents, pubmed-meshheading:21593114-Bone Remodeling, pubmed-meshheading:21593114-Calcium, pubmed-meshheading:21593114-Female, pubmed-meshheading:21593114-Humans, pubmed-meshheading:21593114-Indans, pubmed-meshheading:21593114-Middle Aged, pubmed-meshheading:21593114-Osteoporosis, Postmenopausal, pubmed-meshheading:21593114-Parathyroid Hormone, pubmed-meshheading:21593114-Patient Compliance, pubmed-meshheading:21593114-Phenylpropionates, pubmed-meshheading:21593114-Receptors, Calcium-Sensing, pubmed-meshheading:21593114-Teriparatide
pubmed:year	2011
pubmed:articleTitle	The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
pubmed:affiliation	GlaxoSmithKline, Biopharm Development Unit, 709 Swedeland Road, UM2291, King of Prussia, Pennsylvania 19406, USA. lorraine.a.fitzpatrick@gsk.com
pubmed:publicationType	Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't